Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EGFRBi-armed autologous activated T cells |
Synonyms | |
Therapy Description |
EGFRBi-armed autologous activated T cells are autologous T-cells that have been armed with a bispecific antibody that binds EGFR and CD3, potentially enhancing T-cell mediated response to EGFR-expressing cells upon antibody binding (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EGFRBi-armed autologous activated T cells | EGFR BATs | EGFR Antibody 60 | EGFRBi-armed autologous activated T cells are autologous T-cells that have been armed with a bispecific antibody that binds EGFR and CD3, potentially enhancing T-cell mediated response to EGFR-expressing cells upon antibody binding (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04137536 | Phase I | EGFRBi-armed autologous activated T cells | A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT03269526 | Phase Ib/II | EGFRBi-armed autologous activated T cells | BATs Treatment for Pancreatic Cancer, Phase Ib/II | Active, not recruiting | USA | 0 |
NCT01420874 | Phase I | EGFRBi-armed autologous activated T cells Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) | Completed | USA | 0 |
NCT03344250 | Phase I | EGFRBi-armed autologous activated T cells | Phase I EGFR BATs in Newly Diagnosed Glioblastoma | Active, not recruiting | USA | 0 |
NCT02521090 | Phase Ib/II | EGFRBi-armed autologous activated T cells | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | Withdrawn | 0 | |
NCT01081808 | Phase I | EGFRBi-armed autologous activated T cells | Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | Terminated | USA | 0 |